Lenvatinib inhibits RTK receptors and subsequently blocks its downstream RAS/RAF/MEK/ERK signal transduction pathway, eventually impeding tumor cells proliferation and tumor angiogenesis (Leonetti et al., 2017; Cabanillas and Takahashi, 2018). The gene discussed is MAP2K7; the disease is neoplasm.